ISRCTN38378163已完成2 期
Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 264 人开始时间: 2008年4月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Between 18 (or minimum legal age) and 70 years of age
- •2. Out-patients of both genders
- •3. Fulfilling Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for major depressive disorder (MDD)
排除标准
- •1. Women of childbearing potential without effective contraception
- •2. Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than MDD
- •3. Any clinically relevant abnormality detected during the physical examination, electrocardiogram (ECG) or laboratory tests likely to interfere with the study conduct or evaluations
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks.MedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2007-003312-65-FRInstitut de Recherches Internationales Servier240
进行中（未招募）
不适用
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks.Major Depressive DisorderEUCTR2007-003312-65-LTInstitut de Recherches Internationales Servier240
进行中（未招募）
不适用
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks. - FIGAROMajor Depressive DisorderEUCTR2007-003312-65-EEInstitut de Recherches Internationales Servier240
进行中（未招募）
不适用
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks. - FIGAROMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2007-003312-65-CZInstitut de Recherches Internationales Servier240
进行中（未招募）
不适用
Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks. - FIGAROMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2007-003312-65-FIInstitut de Recherches Internationales Servier240